Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,128

Participants

Timeline

Start Date

February 5, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
BenzodiazepinesBladder CancerDeliriumSurgeryCancer Recurrence
Interventions
DRUG

Remimazolam

Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.

DRUG

Propofol

Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.

Trial Locations (6)

100034

RECRUITING

Peking University First Hospital, Beijin

Unknown

RECRUITING

Beijing Tsinghua Chang Gung Hospital, Beijing

RECRUITING

The Sixth Medical Center of PLA General Hospital, Beijing

RECRUITING

Guizhou Provincial People's Hospital, Guiyang

RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

RECRUITING

Shanghai 10th People's Hospital, Shanghai

All Listed Sponsors
collaborator

Beijing Tsinghua Chang Gung Hospital

OTHER

collaborator

Navy General Hospital, Beijing

OTHER

collaborator

Guizhou Provincial People's Hospital

OTHER

collaborator

Jiangsu Provincial People's Hospital

OTHER

collaborator

Shanghai 10th People's Hospital

OTHER

lead

Peking University First Hospital

OTHER